Business
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
FOSTER CITY, Calif., May 04, 2026--Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":280,"url":"https://media.zenfs.com/en/business-wire.com/6d1feead691e05f5b400bd37501f8a62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WGGVwfZ_AFCbcZy30ffJ_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MA--/https://media.zenfs.com/en/business-wire.com/6d1feead691e05f5b400bd37501f8a62","width":480,"height":280}},"lazy":false},{"type":"text","content":"- Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=<0.0001) reduction in primary endpoint of cholestatic pruritus","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"- Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) scheduled for summer 2026","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"- Full results to be presented in late-breaking oral presentation at the EASL International Liver Congress 2026 ","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"- Mirum to host conference call to discuss Mirum’s recent clinical readouts, today, May 4 at 8:30 am ET","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"FOSTER CITY, Calif., May 04, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, in patients with primary sclerosing cholangitis (PSC).","length":348,"tagName":"p"},{"type":"text","content":"The VISTAS Phase 2b study included 158 patients with PSC who were assigned to either a primary analysis cohort (moderate to severe itch; n=111) or a secondary analysis cohort (mild itch; n=47) based on itch severity at baseline, as measured by the Adult Itch Reported Outcome (ItchRO) scale. Patients in both cohorts were treated with volixibat 20 mg twice daily (BID) or placebo. Per the study protocol, the endpoint was evaluated in the primary analysis cohort.","length":463,"tagName":"p"},{"type":"text","content":"The results of the VISTAS Phase 2b study support the potential for volixibat to become the first treatment for cholestatic pruritus in patients with PSC. In the primary...